Absorbe humedad aunque aumente la temperatura
En este Short os hablamos de un material muy especial que, al contrario que otros, absorbe más humedad cuando aumenta la temperatura exterior. …
Uncategorized
Boudewijn van Lent Named President and CEO of VanDeMark Chemicals
VanDeMark Chemical, Inc., a leading global producer of life science chemistries, announced the appointment of Dr. Boudewijn van Lent as President and CEO, effective immediately.
Boudewijn van Lent Named President and CEO of VanDeMark Chemicals Read More »
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
KalVista Pharmaceuticals, Inc. announced that it made two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary.
Zomedica Exercises Option to Acquire Structured Monitoring Products
Zomedica Corp., announced it has exercised its option to move forward with the acquisition of Structured Monitoring Products, Inc., the makers of VetGuardian™ zero-touch vital signs remote monitoring system, at a previously negotiated purchase price.
Zomedica Exercises Option to Acquire Structured Monitoring Products Read More »
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in China.
Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions
Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions.
Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
Vedanta Biosciences today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI).
Bliss Biopharmaceutical Enters Into a Clinical Trial Collaboration Agreement With an Option of Strategic Collaboration With Eisai for BB-1701
Bliss Biopharmaceutical Co., Ltd announced a clinical trial collaboration agreement with option for strategic collaboration with Eisai Co., Ltd., for BB-1701, eribulin-payload based ADC directed against Human Epidermal Growth Factor Receptor 2 for the treatment of cancers.
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine
Innovent Biologics, Inc. announces that second interim analysis and survival analysis results of the ORIENT-31 study have been published in the Lancet Respiratory Medicine.
Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease
Innovent Biologics, Inc. announces that the first patient with Thyroid Eye Disease has been successfully dosed in the Phase 3 study of IBI311, a recombinant anti-insulin-like growth factor-1 receptor monoclonal antibody.